CORE Kidney

Fabry Disease

Sanofi – PERIDOT

Drug name: Venglustat

  • Phase 3, double-blinded, Placebo-controlled
  • Mechanism: Glucosylceramide synthase (GCS) inhibitor 

Key inclusion criteria:

  • Age ≥ 18
  • Confirmed diagnosis of Fabry disease
  • Participants who are treatment-naïve or without prior treatment with an approved or experimental therapy for Fabry disease within at least 6 months prior to screening

Key exclusion criteria:

  • Estimated glomerular filtration rate <60 mL/min/1.73 m2
  • A history of drug and/or alcohol abuse within the past year prior to the screening visit. A history of alcohol dependence within the 5 years prior to the screening visit.

Study Coordinator: Josh Ooka 
[email protected]